Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has announced the release date of its full year earnings for 2009. The results will be posted on the company’s website, http://www.vrtx.com/, on Thursday, February 4, 2010, after the close of the financial markets. The company will follow the release with a conference call at 5:00 pm ET that evening.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
The conference call will be accessible via webcast on the Events & Presentations page of the company’s website. After the end of the call, the webcast will remain on the site as a replay until February 11, 2010. Live listeners are encouraged to log on early to allow ample time to register and download and install any necessary audio software.
Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company’s principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment in clinical development that targets hepatitis C virus (HCV) infection. As of December 31, 2008, Vertex was also developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis (CF). In March 2009, the Company completed its acquisition of ViroChem Pharma Inc., a company with two investigational HCV polymerase inhibitors in clinical development.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
